About 44% of U.S. employers with 500 or more employees now cover weight-loss drugs in 2024, a slight increase from 41% in 2023, reflecting growing acceptance.
The survey found that 64% of U.S. employers with over 20,000 employees now cover weight-loss drugs, an increase from 56% last year, indicating a trend toward wider coverage.
Cost concerns are significant, prompting employers to implement authorization requirements, ensuring that medications are primarily used by those who will benefit most.
Currently, only about 24.4 million Americans have access to GLP-1 drugs through commercial health plans, highlighting a gap in availability despite increasing employer coverage.
Collection
[
|
...
]